We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Gilead Sciences may have some exciting prospects on the horizon, but for now, its cash-cow hepatitis C business is a big drag. After hepatitis C sales cratered in the first quarter—falling even more than expected...